I can tell you the response to your first question will no doubt...

I can tell you the response to your first question will no doubt be: "Expanding the available sites from 18,000 labs to 270,000 gp offices will expand the addressable market and expand the reach of the product. As the product is designated to point of care, the gp office is our primary target for sale and likely see further uptake of the product".

But I agree, there is sole focus on Febridx more than anything, likely because the Viradx product whilst marketable, it saturated with other products as well. Febridx is a unique product in market.

Question is, what revenue this quarter from the product sales would make people happy? Surely it needs to be well over $1.2Million given the half year sales and previous quarters saw similar numbers.

FY23 had $300,000 USD in sales
FY24 had $1.2Million USD in sales
FY25: xxx

If the quarter shows above the $1.2Million mark, surely they is a drastic increase in product sales, the market shouldn't ignore? Given CLIA waiver not provided, if that kind of quarterly revenue is received, with CLIA waiver, the revenue could be expanded 15x. Even if the lowest sales year is multiplied by the addressable market with CLIA waiver, the annual revenue could be as little as $4.5Million.